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ABSTRACT 
An epileptic patient on high dose carbamazepine monotherapy received erythromycin from 
a physician and ketoconazole from a dermatologist. Carbamazepine neurotoxicity developed as a 
result of a pharmacokinetic interaction between the three drugs. Precautions are suggested to 
minimize the risk of such drug interactions that span medical specializations. 
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Drug interactions are of two types: 
pharmacokinetic and pharmacodynamic. 
Pharmacokinetic interactions are those which 
involve drug absorption, protein-binding, distri-
bution, metabolism and excretion; fluoxetine-
mediated inhibition of the metabolism of tricyclic 
antidepressant drugs is an example of a 
pharmacokinetic interaction. Pharmacodynamic 
interactions are those which involve physiologi-
cal effects through receptor or other mecha-
nisms; cyproheptadine-mediated reversal of the 
antidepressant benefits of fluoxetine is an ex-
ample of a pharmacodynamic interaction. 
Pharmacokinetic interactions are of much 
importance in psychiatry because many psycho-
tropic and antiepileptic agents commonly induce 
or inhibit the metabolism of other drugs through 
their action on the cytochrome P450 hepatic 
microsomal enzymes. A less common situation 
is one in which non-psychotropic drugs exert 
pharmacokinetic effects on psychotropic medi-
cations; such interactions are of importance 
because they span medical specializations, and 
may arise because the concerned specialists 
do not take cognizance of interactions across 
treatment domains. 
This report illustrates a multiple drug in-
teraction that arose from independent prescrip-
tions issued by a psychiatrist, a physician and a 
dermatologist. Suggestions are offered to guard 
against the occurrence of such situations. 
CASE REPORT 
Mr. R, a 40 year old epileptic, was fit-free 
for the past 2 years on monotherapy with car-
bamazepine 1200 mg/day in 3 divided doses. 
His carbamazepine blood level was 12mg/l.during 
January 1999, he consulted a physician for a 
respiratory infection and was prescribed eryth-
romycin 250 mg four times daily. On the same 
day, he consulted a dermatologist for a fungal 
infection, and was prescribed ketoconazole 200 
mg/day. On the second day of erythromycin and 
ketoconazole, he began to experience a squint-
ing sensation. By the third day, he developed 
diplopia, giddiness, slurring of speech and un-
steadiness of gait. Physical examination re-
vealed lateral gaze nystagmus, marked incoor-
dination on various tests, and other cerebellar 
signs. There were no other abnormal physical 
findings. Cognition was grossly intact. His 12 
hr. carbamazepine level was found to be 25.0 
mg/L. 
75 CHITTARANJAN ANDRADE 
Carbamazepine neurotoxicity was diag-
nosed, secondary to a multiple drug interaction, 
and all medication was stopped for a day. The 
neurotoxicity began to subside. Carbamazepine 
alone was resumed the next day in a gradually 
escalating dose. The upward dose titration was 
based on carbamazepine blood levels which 
were obtained daily to ensure that these were 
below toxic (15-20 mg/L) but not below the thera-
peutic range (6-12 Mg/L). After a week, the origi-
nal dose and blood level were re-attained, and 
the patient remained symptom-free. 
DISCUSSION 
About 98% of carbamazepine is cleared 
by hepatic metabolism (Ciraulo and Slattery, 
1995) through the cytochrome P450 3A3/4 
microsomal enzymes (Preskorn, 1996), and this 
metabolism is inhibited by erythromycin and 
other macrolide antibiotics; there are several 
reports on record of the development of 
carbamazepine neurotoxicity following the 
administration of a macrolide antibiotic with 
carbamazepine (Janicak, 1993; Ciraulo & 
Slattery, 1995). Patients who are on high doses 
of carbamazepine, such as the patient in the 
present case report, are therefore especially 
vulnerable to such interaction- mediated 
toxicity. 
Ketoconazole, a broad-spectrum anti-fun-
gal agent, is also a potent inhibitor of the 3A3/4 
enzyme system (Greenblatt, 1993). Being a rela-
tively new drug, there are few reports of its ef-
fects on carbamazepine levels, in one such re-
port, Spina et al. (1997) demonstrated that 
ketoconazole 200 mg/day increased plasma car-
bamazepine (but not its epoxide metabolite) con-
centrations by about 25%. 
It is therefore likely that the patient in the 
present report developed carbamazepine 
neurotoxicity as a combined pharmacokinetic in-
teraction between carbamazepine on the one hand 
and erythromcin and ketoconazole on the other. 
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'Correspondence 
It is suggested that treating doctors neec 
to be aware of psychotropic - medical drug in-
teractions such as that between carbamazepine 
and erythromycin or ketoconazole. Psychiatrists 
also need to routinely warn patients about spe-
cific hazardous interactions between psycho-
tropic and medical drugs; for example the pa-
tient can be given a short list of drugs that are 
best avoided. Such a precaution is especially 
important when patients are on high doses of 
psychotropic medication. It is not prudent to 
assume that the patient will discuss his psycho-
tropic prescription with physicians from other 
specialization, nor is it prudent to assume that 
other specialists will be aware of all interactions 
between medical and psychotropic agents. 
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